Granite Point Capital Management, L.P. Nu Cana PLC Transaction History

Granite Point Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$1.95 - $2.85 $1.57 Million - $2.29 Million	-802,940 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.7 - $5.04 $365,015 - $681,362	135,191 Added 20.25%	802,940 $2.22 Million
Q1 2021 May 12, 2021	BUY	$4.38 - $7.0 $101,357 - $161,987	23,141 Added 3.59%	667,749 $3.33 Million
Q4 2020 Feb 05, 2021	SELL	$4.4 - $5.59 $683,724 - $868,641	-155,392 Reduced 19.42%	644,608 $2.89 Million
Q3 2020 Nov 06, 2020	BUY	$4.57 - $6.48 $3.66 Million - $5.18 Million	800,000 New	800,000 $4.14 Million

3.34M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $103M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.